BiotechTube

Evacetrapib + Atorvastatin + Ezetimibe + Placebo

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Oct 1, 2014 → Dec 1, 2015

NCT ID
NCT02227784

About Evacetrapib + Atorvastatin + Ezetimibe + Placebo

Evacetrapib + Atorvastatin + Ezetimibe + Placebo is a phase 3 stage product being developed by Eli Lilly for Hyperlipidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02227784. Target conditions include Hyperlipidemia.

What happened to similar drugs?

8 of 20 similar drugs in Hyperlipidemia were approved

Approved (8) Terminated (1) Active (12)
✅Diet+pravastatinDaiichi SankyoApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
✅Rosuvastatin (Crestor)AstraZenecaApproved
✅simvastatin + EzetimibeMerckApproved
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02227784Phase 3Terminated

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
DRL-17822 or placeboDr. Reddy's LaboratoriesPhase 2
32
VK2809 + PlaceboViking TherapeuticsPhase 2
32
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
40
Diet+pravastatinDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
43
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
40
exenatideEli LillyPre-clinical
26
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
29
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
29
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
35
Rosuvastatin (Crestor)AstraZenecaApproved
39
simvastatin + EzetimibeMerckApproved
43
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
40
simvastatin 20 mg/ezetimibeMerckPhase 2/3
38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
47
Sitagliptin + PlaceboMerckPhase 2/3
38